About SoniVie
SoniVie is a Healthcare company based in Rosh Haayin (Israel) founded in 2014, and was acquired by Boston Scientific in March 2025. A denervation catheter for pulmonary hypertension treatment is developed. SoniVie has raised $62.5 million across 2 funding rounds from investors including Boston Scientific, Andera Partners and Supernova Invest. Its chief executive, as recorded, is Tomaso Zambelli. SoniVie offers products and services including TIVUS System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is SoniVie Ltd.
Company details
SoniVie was founded in 2014 in Rosh Haayin, Israel, within the medical device sector focused on cardiovascular treatments. A therapeutic intra-vascular ultrasound catheter, known as TIVUS, is developed to target nerves in the pulmonary artery associated with disease progression. This device is inserted into the artery to selectively damage relevant nerves while avoiding contact with vessel walls or adjacent tissues, supporting non-invasive interventions for pulmonary hypertension management.
- Headquarters Rosh Haayin, Israel
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website sonivie.com
- Social LinkedIn
- Acquired by Boston Scientific (Mar 2025)
- Legal Name Sonivie Ltd.
- Total Equity Funding$62.5M (USD)
in 2 rounds
- Latest Funding Round$60M (USD), Series C
Jan 2023
- InvestorsBoston Scientific
& 5 more
- Acquired byBoston Scientific
(Mar 2025)
Products & Services of SoniVie
SoniVie offers a comprehensive portfolio of products and services, including TIVUS System.
Ultrasound-based system for renal denervation to reduce hypertension.
Funding Insights of SoniVie
SoniVie has successfully raised a total of $62.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.5M
- Total Rounds 2
- Last Round Series C — $60M
- First Round $2.5M
(Nov 2015)
- Investors Count 5
All 2 funding rounds of SoniVie with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $60M | Series C | – | Andera Partners | |
| Nov 2015 | $2.5M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in SoniVie
SoniVie has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Andera Partners and Supernova Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
| supernovainvest.com | ||||
Venture capital firm | omegafunds.com | Boston, United States | ||
| techwald.com | ||||
| accelmed.com | ||||
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for SoniVie
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SoniVie
7 people are tracked at SoniVie (6 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Tomaso Zambelli | CEO | Leadership |
Ophir Coriat | Director Of Operations | Leadership |
Jason Jones | Global Vp, Clinical Affairs | Leadership |
Yael Katzir Levy | Director Of Finance | Leadership |
Janelle J. | Clinical Affairs Director | Leadership |
Alessandro Rotilio | Director Of Clinical And Regulatory Operations - Europe | Leadership |
Tracy Hover | Field Clinical Engineer | Team |
Complete people profiles for SoniVie
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SoniVie
4 dated milestones of SoniVie across 11 years, from founding to its latest funding, stage changes and deals.
- Founded SoniVie is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series C, of $60.0M.
- Exit Acquired by Boston Scientific.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sonivie
Complete news archive for SoniVie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SoniVie
SoniVie was founded in 2014 and raised its 1st funding round 1 year after it was founded.
SoniVie is headquartered in Rosh Haayin, Israel. It is registered at Rosh Haayin, Central District, Israel.
Tomaso Zambelli is the CEO of SoniVie, as recorded in our data.
SoniVie is a funded company, having raised a total of $62.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2.5M, raised on Nov 2015.
SoniVie was founded in 2014 in Rosh Haayin, Israel, within the medical device sector focused on cardiovascular treatments. A therapeutic intra-vascular ultrasound catheter, known as TIVUS, is developed to target nerves in the pulmonary artery associated with disease progression. This device is inserted into the artery to selectively damage relevant nerves while avoiding contact with vessel walls or adjacent tissues, supporting non-invasive interventions for pulmonary hypertension management.
SoniVie offers TIVUS System.
SoniVie has 6 investors. Key investors include Boston Scientific, Andera Partners, Supernova Invest, Omega Funds, and TechWald Holding.
SoniVie operates through Sonivie Ltd..
Yes. SoniVie was acquired by Boston Scientific in March 2025.